I just perused the San Antonio Breast Cancer Symposium and the only thing that I could find for Kosan is an abstract for a poster with the preliminary results of the Phase II trial in combination with Herceptin. Could be interesting. I couldn't find anything else regarding Hsp90 inhibitors, but I didn't go through everything.
Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: preliminary results.
Modi S, Stopeck A, Linden HM, Sugarman S, Ma W, Solit D, Rosen N, Kersey K, Johnson RG, Hannah AL, Hudis C. Memorial Sloan-Kettering Cancer Center, New York, NY; Arizona Cancer Center, Tucson, AZ; University of Washington, Seattle, WA; Kosan Biosciences, Inc., Hayward, CA. |
